checkAd
    Startseite > Aktien > Dare Bioscience > Nachrichten
    Dare Bioscience Aktie
    0,2745
     
    EUR
    -6,63 %
    -0,0195 EUR
    Letzter Kurs 14:05:22 Tradegate
    0,2745
     
    EUR
    3.300 STK
    Geldkurs 14:05:23
    0,2950
     
    EUR
    3.000 STK
    Briefkurs 14:05:23
    ISIN: US23666P1012 · WKN: A2DU45 · SYM: 1221 · USA

    Neueste Nachrichten

    Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update
    14:00 Uhr · globenewswire · Dare Bioscience
    Daré Bioscience to Host First Quarter 2024 Financial Results and Company Update Conference Call and Webcast on May 14, 2024
    07.05.24 · globenewswire · Dare Bioscience
    Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network
    02.05.24 · globenewswire · Dare Bioscience
    Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts
    30.04.24 · globenewswire · Dare Bioscience
    Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
    23.04.24 · globenewswire · Dare Bioscience
    Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene: an Investigational Hormone-Free Monthly Intravaginal Contraceptive
    11.04.24 · globenewswire · Dare Bioscience
    Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update
    28.03.24 · globenewswire · Dare Bioscience
    Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024
    21.03.24 · globenewswire · Dare Bioscience
    Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting
    22.02.24 · globenewswire · Dare Bioscience
    Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024
    31.01.24 · globenewswire · Dare Bioscience
    Daré Bioscience Announces Executive Team and Board of Directors Changes
    26.01.24 · globenewswire · Dare Bioscience
    Daré Bioscience Announces Grant to Support Biotherapeutic Product Development
    17.01.24 · globenewswire · Dare Bioscience